MITSUBISHI-HEAVY-IND
18.4.2019 09:23:11 CEST | Business Wire | Press release
Premiering for the first time in the world, Mitsubishi Heavy Industries Thermal Systems, Ltd., a Group company of Mitsubishi Heavy Industries, Ltd. (MHI) (TOKYO: 7011), is adopting R454C, a refrigerant with an extremely low global warming potential (GWP), in a 1-horsepower (HP) class residential air-conditioner. The conventional shortcomings of the R454C,for example; inferior heat exchanger performance attributable to it being a mixed refrigerant have been overcome through the use of proprietary technology that optimize the heat exchanger’s flow volume and other measures. The company has already developed a demonstration unit of the residential air-conditioner featuring R454C and preparations are underway towards mass production with an eye on an initial launch into the European market, where environmental regulations are particularly stringent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005241/en/
The R454C refrigerant has an ozone depletion potential (ODP) of 0 (zero) and a GWP of 146 (CO2 =1). The latter value is approximately 1/14th and 1/5th the respective GWP levels of refrigerants currently and most widely used in air-conditioners of small/medium scale: R410A (2090) and R32 (675). The overall global warming impact (GWP x refrigerant volume) from the demonstration unit’s refrigerant represents a 91.3% reduction from the level of MHI Thermal Systems’ previous model for the European market*1 .
Worldwide initiatives aimed at stopping global warming were strengthened in October 2016 with the adoption of the “Kigali Amendment” to the Montreal Protocol on Substances that Deplete the Ozone Layer. Named after the capital city of Rwanda where the delegates met, the Kigali Amendment mandates progressive reduction in hydrofluorocarbons (HFC), substances that do not deplete the ozone but do adversely impact global warming*2 . In addition, since 2015 the member nations of the European Union (EU), where environmental awareness is deeply entrenched, have gradually expanded regulations affecting the sale and usage of substances, including HFCs, that have GWP values of 150 and higher, contributing to global warming. MHI Thermal Systems’ development of the world’s first small-capacity residential air-conditioner adopting the R454C refrigerant is thus a leading and positive response to these international movements.
Going forward, MHI Thermal Systems will continue to dedicate its resources to developing and marketing high-performance products using low-GWP refrigerants, thereby contributing to protection of the global environment in markets everywhere.
|
Notes |
||||
|
*1: |
The top-of-the-line SRK25ZSX-S with a piping length of 5m, which adopts the R410A refrigerant |
|||
|
*2: |
These substances are subject to the terms of both the Montreal Protocol (1987) and the preceding Vienna Convention for the Protection of the Ozone Layer (1985). |
|||
About Mitsubishi Heavy Industries Group
Mitsubishi Heavy Industries, Ltd. (MHI), headquartered in Tokyo, is one
of the world’s leading industrial firms with 80,000 group employees and
annual consolidated revenues of around 38 billion U.S. dollars. For more
than 130 years, the company has channeled big thinking into innovative
and integrated solutions that move the world forward. MHI owns a unique
business portfolio covering land, sea, sky and even space. MHI delivers
innovative and integrated solutions across a wide range of industries
from commercial aviation and transportation to power plants and gas
turbines, and from machinery and infrastructure to integrated defense
and space systems.
For more information, please visit MHI’s
website: www.mhi.com/index.html
For
Technology, Trends and Tangents, visit MHI’s new online media SPECTRA
:
spectra.mhi.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190418005241/en/
Contact:
PRESS CONTACT: Corporate Communication Department Mitsubishi Heavy Industries, Ltd. James Bennett, +81-(0)3-6275-6200 Email: mediacontact_global@mhi.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom